{
    "metadata": {
        "title": "Huntington Disease  Occupational Therapy",
        "synonyms": [
            "huntington\u2019s disease",
            "huntington chorea",
            "huntington\u2019s chorea",
            "chronic progressive hereditary chorea",
            "chorea, huntington\u2019s: huntington\u2019s chorea"
        ],
        "anatomical location body part affected": [
            "Nervous system  motor and cognition. Can also affect mental health. Atrophy occurs in the caudate, putamen, and paravermis in the cerebellum and in the cortical interneurons(1,13)"
        ],
        "area of specialty": [
            "neurological rehabilitation"
        ],
        "description": [
            "Huntington disease (HD) is an inherited autosomal dominant neurodegenerative disease that is progressive in nature(1,2,3,4,13,26)",
            "Someone with an HD-affected  parent has a 50% chance of inheriting the HD gene(1,2,3,13)",
            "Symptoms usually present at 30\u201350  years of age, but onset can be at any age between 2 and 70 years(1,13)",
            "Main features are involuntary movements (chorea), psychiatric disturbance, and cognitive decline(1,13,26)",
            "Prevalence \u2013Based on age-adjusted  studies, the estimated prevalence of HD in Canada is 13.7 per 100,000 persons. In the United States, HD affects between 6.52 and 12.7 per 100,000 persons(15) \u2013A 2016 systematic review indicates that the prevalence of HD has increased per decade between 15%-20%  in North America (between 1950 and 2012), Australia (between 1954 and 1996), United Kingdom (between 1950 and 2010, and Western Europe (between 1930 and 2007).(14) Worldwide, the lowest rates of HD were found among Asian populations and the highest in Caucasians(14) -The authors theorize that the rise in prevalence of HD in these regions is influenced by:(14) -Physician awareness and availability of genetic testing -Less negative stigma (or shame) associated with a family history of HD -Change or increase in genetic mutation rate -Increase in population survival rates and more effective management of symptoms or application of equipment  Decreased ability to self-feedMaximize independence and safety with self-feedingFunctional training _ Teaching patient to put arms on table to stabilize proximal joints when eating _ _ Minimize environmental distractions during meals (e.g., turn off television or radio) _ _ Prescription, application of devices and equipment _ Adaptive equipment such as scoop dishes, large- handled or weighted utensils,(12,31,32) and non-slip placematsContinual reevaluation of amount of assistance with feeding the patient needs as patient\u2019s function deterioratesProvide patient and family/ caregivers with written instructions regarding functional activities that can be performed at home and correct use and/ or application of equipment . Desired Outcomes/Outcome Measures"
        ],
        "indications": [],
        "ICD-9 codes": {},
        "ICD-10 codes": {
            "G10": "Huntington\u2019s disease (ICD codes are provided for the reader\u2019s reference and not for billing purposes)"
        },
        "ICD-11": {},
        "G-codes": {},
        "CPT codes": {},
        "HCPCS codes": {},
        "reimbursement": [],
        "presentation signs and symptoms": [
            "The onset of cognitive symptoms may precede motor signs and symptoms in patients with HD(17,22)",
            "Motor signs and symptoms \u2013Chorea: complex, nonrepeating, involuntary movements of the limbs \u2013Ballism: involuntary movements of upper extremity, usually unilateral and sometimes violent  \u2013Athetosis: slow, writhing movements \u2013Tics: repeated \u201cspasmodic\u201d movements of the face and upper extremities \u2013Myoclonus \u2013 involuntary \u201cjerks\u201d\u2019 \u2013Dystonia \u2013 movement with spasm \u2013Late changes include bradykinesia and rigidity(1,2,3,4,5,13) \u2013Akinesia \u2013 impairment or loss of voluntary movement \u2013Gait disturbance(1) \u2013Oculomotor abnormalities(1,13) -Seen early in onset -Excessive blinking and greater latency of response \u2013Poor coordination(1) \u2013Slow reaction time(1) \u2013Changes in handwriting(2)",
            "Cognitive signs and symptoms \u2013Impaired executive function(1,2,13) \u2013Memory impairment(2) \u2013Attention impairment(2) \u2013Dysarthria(1) \u2013Language difficulties in later stages(1,2,3,4,5) \u2013Dementia(1) \u2013Difficulty learning new things(2)",
            "Psychiatric/behavioral signs and symptoms(1,5) \u2013Depression(1,5,13) \u2013Anxiety(1,5,13) \u2013Aggression(1,5,13) \u2013Impulsiveness(1,5,13) \u2013Obsessive-compulsive  disorder(1,5,13) \u2013Mania(1,5,13) \u2013Personality changes(1,5,13) \u2013Psychosis(1,5,13) \u2013Suicide(1,5,13) -Suicide rate is 5 times that of the general population(13) \u2013Euphoria(1) \u2013Irritability(1)",
            "Dysphagia is a complication of HD in later stages",
            "Westphal variant of HD: includes cognitive dysfunction, bradykinesia, and rigidity; more common in juvenile-onset  HD(13) Causes, Pathogenesis, & Risk Factors"
        ],
        "contraindications precautions to test": [
            "Use of gait belt for safety in transfers, as impaired judgment and decreased motor control put patient at risk for falls(4)",
            "Remove any hazardous objects from area to prevent the patient from hitting or falling into them",
            "For patients with late-stage  HD who are immobile, clinicians should check frequently for skin breakdown in bed, wheelchair, as applicable"
        ],
        "psychometric properties": [],
        "potential complications adverse effects": [],
        "test preparation materials required": [],
        "test procedure": [],
        "test scoring interpretation": []
    },
    "causes & risk factors": {
        "causes": [
            "Hereditary, autosomal dominant"
        ],
        "pathogenesis": [
            "Cellular loss in neurons in the caudate nucleus and putamen(1,2,3,4,5)",
            "Huntingtin gene ( HTT) located on chromosome 4(1,2,3,7,13)",
            "There is a segment of the HTT gene called the CAG trinucleotide.(1,2,3,5,7)The CAG trinucleotide repeats on the HTT gene,leading to production of excess glutamate. Excess glutamate units lead to cellular death in basal ganglia cells(1,3)\u2013CAG repeat lengths of 40 or above cause HD(1,3,4)\u2013CAG repeat lengths of 50 or above are associated with an early onset (< 21 years)(1,2,3,4)",
            "Altered basal ganglia cells affect output to the thalamus, which affects motor output(3)",
            "Atrophy is seen in the caudate, the putamen, and the paravermis in the cerebellum and in the cortical interneurons(1,2,3,4,13)"
        ],
        "risk factors": [
            "Family history(14,15)",
            "Chance of inheritance occurs in every generation(3,5,7)",
            "White race(14,15)"
        ]
    },
    "indications for procedure": [],
    "overall contraindications precautions": [
        "Check to see if dysphagia is a problem; note any soft diet, thin liquid restrictions",
        "Safety is a primary concern for patients with HD, as poor judgment, memory loss, and mania can be present(1,2,3)",
        "Patients with this diagnosis are at risk for falls; follow facility protocols for fall prevention and post fall-prevention instructions at bedside, if inpatient. Ensure that patient and family/caregivers are aware of the potential for falls and educated about fall-prevention  strategies. Discharge criteria should include independence with fall-prevention strategies(4)",
        "Clinicians should follow the guidelines of their clinic/hospital and what is ordered by the patient\u2019s physician. The summary below is meant to serve as a guide, not to replace orders from a physician or a clinic\u2019s specific protocols",
        "Caution should be used with restraints in seating and in bed, as restraints can often cause more harm. Clinicians should assess positioning in bed and chair for support and safety. Follow facility protocol and state law for restraint use. Restraints usually require a physician order and frequent monitoring",
        "For patients with late-stage  HD who are immobile, clinicians should check frequently for skin breakdown with positioning devices",
        "There is a high risk of suicide (5x greater than in the general population) in patients with HD(5,13) \u2013 contact the patient\u2019s physician for any signs of suicidal thoughts",
        "See specific  Contraindications/precautions to examination   and  Contraindications/precautions   under Assessment/"
    ],
    "contraindications precautions to procedure": {},
    "guidelines for use of procedure": {},
    "examination": {
        "contraindications precautions to examination": [
            "Use of gait belt for safety in transfers, as impaired judgment and decreased motor control put patient at risk for falls(4)",
            "Remove any hazardous objects from area to prevent the patient from hitting or falling into them",
            "For patients with late-stage  HD who are immobile, clinicians should check frequently for skin breakdown in bed, wheelchair, as applicable"
        ],
        "history": {
            "history of present illness": {
                "mechanism of injury or etiology of illness": "When was HDdiagnosed in the patient? What has been the general progression of the disease? Any complications?",
                "course of treatment": {
                    "medical management": "Document treatments received",
                    "surgical management": [],
                    "medications": "Determine what medications clinician has prescribed; are they being taken? Does the patient feel they are effective?(1,2,3,4,5,6) Tetrabenazine Amantadine (Symmetrel) Riluzole (Rilutek) Nabilone (short-term  only) Other medications that can be used for chorea(1) Olanzapine (Zyprexa) Clozapine  Aripiprazole(1) Deutetrabenazine(23) New medication designed to reduce CYP2D6 metabolism. In a double-blind  randomized controlled clinical trial, use of the medication resulted in improvements at 12 weeks compared to placebo, but additional research is needed to compare its effectiveness with that of other medications Botulinum toxin type A may be used for dystonia/spasticity(1) Benzodiazepines for rigidity(1) risperidone (Risperdal) fluoxetine (Prozac) sertraline (Zoloft) nortriptyline (Pamelor) lithium (Eskalith, Lithobid) mirtazapine haloperidol(1) Valproic acid for myoclonus/hyperkinesis(1)",
                    "diagnostic tests completed": [
                        "Diagnostic tests completed:  Usual tests for this condition are the following:(1)",
                        "In an individual with an established family history experiencing onset of symptoms, no further testing is required(1,2,5,7)",
                        "Genetic testing to confirm or predict diagnosis, including testing for CAG repeats(5,7,13)",
                        "CT scan",
                        "MRI"
                    ],
                    "alternative therapies": "Document any use of home remedies (e.g., ice or heating pack) or alternative therapies (e.g., acupuncture) and whether or not they help",
                    "previous therapy": "Document whether patient has had occupational, physical, or speech therapy for this or other conditions and what specific treatments were helpful or not helpful"
                },
                "aggravating easing factors": "Document what aggravates symptoms (and length of time each item is performed before the symptoms are worsened). Document what eases symptoms (and length of time each item is performed before the symptoms are eased)",
                "body chart": "Use body chart to document location and nature of symptoms",
                "nature of symptoms": "Document nature of symptoms and note quality of voluntary movements, both gross and fineslowed, writhing, posturing, or rapid, flinging movements",
                "rating of symptoms": "Use a visual analog scale (V AS) or 010  scale to assess symptoms at their best, at their worst, and at the moment (specifically address if pain is present now and how much ). Use nonverbal scales as appropriate",
                "pattern of symptoms": "Document changes in symptoms throughout the day and night, if any (a.m., mid-day,  p.m., night); also, document changes in symptoms due to weather or other external variables",
                "sleep disturbance": "Document number of wakings/night -Sleep disturbances may be one of the earliest changes seen in HD(22) -The findings of a study designed to determine if sleep abnormalities are present in the premanifest stage of HD indicate that HD gene carriers have disturbed sleep patterns (i.e., fragmented sleep patterns) compared to controls and that onset of sleep problems occurred coincidently with the development of \u201ccognitive, affective, and subtle motor deficits\u201d -Based on a study of 38 premanifest subjects with HD gene mutation and 36 sex- and age-matched controls",
                "other symptoms": "Document other symptoms patient may be experiencing that could exacerbate the condition and/or symptoms that could be indicative of a need to refer to physician",
                "respiratory status": "Assess whether dyspnea occurs with activityAssess patient\u2019s ability to follow commands, noting how many step commands he or she is able to follow. Cognitive deficits are common in this population -Are there any barriers to learning? Yes__ No__ -If Yes, describe _________________________ "
            },
            "medical history": {
                "past medical history": {
                    "previous history of same similar diagnosis": "Document family history of HD",
                    "comorbid diagnoses": "Ask patient about other problems, including diabetes, cancer, heart disease, psychiatric disorders, and orthopedic disorders",
                    "medications previously prescribed": "Obtain a comprehensive list of medications prescribed and/or being taken (including OTC drugs)",
                    "other symptoms": "Ask patient about other symptoms he or she may be experiencing. Common side effects of medications include fatigue, restlessness, and hyperexcitability(2)"
                }
            },
            "social and occupational history": {
                "patient\u0432\u0402\u2122s goals": "",
                "vocation avocation and associated repetitive behaviors, if any": "Document patient\u2019s work history and ability to participate in work currently. Document patient\u2019s leisure activities and ability to participate in leisure activities currently",
                "functional limitations assistance with ADLs adaptive equipment": "Document amount of assistance patient requires with ADLs. Document any adaptive equipment he or she is currently using",
                "living environment": "Document patient\u2019s living arrangement, with whom patient lives, stairs, number of floors in home, any current bathroom modifications. Identify if there are barriers to independence in the home and any modifications needed"
            }
        },
        "relevant tests and measures": {
            "general": "(While tests and measures are listed in alphabetical order, sequencing should be \u203aRelevant tests and measures: (While tests and measures are listed in alphabetical order, sequencing should be appropriate to patient medical condition, functional status, and setting)",
            "anthropometric characteristics": "BMI \u2013Progressive weight loss may occur at the onset of HD(22)",
            "assistive and adaptive devices": "Assess patient\u2019s use of assistive devices for mobility, adaptive equipment to increase safety and independence in ADLs. Consider pressure-relieving cushions and mattresses for patients with impaired mobility",
            "balance": " Balance \u2013Tinetti Gait & Balance Scale(1,8,9,11,24,25,26,27) \u2013 measures sitting and standing balance, ability to stand from sitting, and gait on a 28-point  scale \u2013Berg Balance Measure(8,11,24,25,26,27)",
            "cardiorespiratory function and endurance": [],
            "circulation": "",
            "functional mobility": "",
            "gait locomotion": " Gait/locomotion \u2013Assess patient\u2019s gait; refer to physical therapy as appropriate for gait training \u2013Assess wheelchair mobility as indicated  \u2013Tinetti Gait & Balance Scale(1,8,11) \u2013 measures sitting and standing balance, ability to stand from sitting, and gait -The Tinetti has been found to have high test-retest reliability over a 6-week  period and concurrent validity in ambulatory patients with HD(8,11,24,25,26,27) Motor function (motor control/tone/learning) \u2013Assess muscle tone in bilateral UE, LE, and trunk \u2013Assess coordination \u2013Motor subsection of Unified Huntington\u2019s Disease Rating Scale (UHDRS) assesses maximal dystonia, maximal chorea, retropulsion pull test (response to sudden pull test), finger taps, pronation/supination, Luria (fist-hand-palm test), rigidity, bradykinesia(10,11,24,25,26,27)",
            "muscle strength": "Manual muscle testing (MMT) for all extremities that have no tone or coordination issues. MMT may be difficult with this patient population because of cognitive difficulties; can assess strength through functional activities",
            "observation inspection palpation including skin assessment": [
                "Motor subsection of UHDRS assesses dysarthria, tongue protrusion(10)",
                "Assess for difficulties in feeding; refer to speech therapy as appropriate for swallowing, communication difficulties \u2022Perception  (e.g., visual field, spatial relations)",
                "Motor subsection of UHDRS assesses ocular pursuits, saccade initiation, and saccade velocity(10)"
            ],
            "posture": "Observe patient\u2019s posture in sitting; note amount of trunk support needed to maintain upper body function. Note any postural instability during movement/activity",
            "range of motion": "Assess active and passive ROM in all extremities. Note any asymmetry or abnormalities Self-care/activities  of daily living  (objective testing)fecal incontinence, urinary incontinence, grooming, toileting, feeding, transfers, walking, dressing, stairs, and bathingwriting, eating, donning and doffing jacket, lifting book to place on shelf, picking up a coin, turning 360\u00b0, walking, stairs",
            "self-care activities of daily living": "",
            "reflex testing": "",
            "sensory testing": "Assess light touch/deep pressure, pinprick, proprioception, vibration, and temperature",
            "special tests specific to diagnosis": " Special tests specific to diagnosis \u2013Behavior Observation Scale Huntington (BOSH) (1,2) -Assessment of clinical features and course of HDADLs, social-cognitive functioning, and mental rigidity and aggression \u2013UHDRS(4,10) -One of the subsections, Total Functional Capacity, measures the level of function in areas of workplace, finances, domestic chores, ADLs, and need for skilled or unskilled care -Other subsections are motor assessment, cognitive assessment, and behavior assessment(1,2,3,4,5,8,9,10) -The UHDRS-For  Advanced Patients (UHDRS-FAP)  has been developed to address the ceiling effects of the UHDRS in those with late-stage  HD -UHDRS-FAP  consists of cognitive, motor, and behavioral sections -Authors of a 2019 study found that the UHDRS-FAP  was more sensitive to motor and cognitive decline than the UHDRS in those with advanced HD(10) \u2013HD-CAB  has been found to have large effect sizes with respect to disease status and high reliability(16) -A cognitive battery designed specifically for use in late premanifest and early HD -Made up of six tests that demonstrated sensitivity to disease status and acceptable reliability -Symbol Digit Modalities Test, Paced Tapping, One Touch Stockings of Cambridge (abbreviated), Emotion Recognition, Trail Making B, and Hopkins Verbal Learning Test ",
            "speech and language examination": "",
            "neurological examination": "",
            "oral structure and oral motor function": "",
            "perception": "",
            "arousal attention cognition": " Arousal, attention, cognition (including memory, problem solving) \u2013Zung Depression Scale(1,4,7,11) \u2013 questionnaire consisting of 20 items about symptoms usually associated with depressionorientation, registration, attention and calculation, language, and recall \u2013Beck Depression Inventory(7) \u2013Hamilton Rating Scale for Depression(7) \u2013Huntington\u2019s Disease Cognitive Assessment Battery (HD-CAB)(16) \u2013 see description under  Special Tests  below \u2013Results from a 3-year  longitudinal study of 559 gene-positive cases in the United States suggest that the cognitive onset of HD may precede motor signs and symptoms(17) \u2013Authors of a retrospective study examined potential relationships between symptoms and functional outcomes of 6,316 individuals in the European HD registry.This study found that 42.4% of individuals with HD reported at least one cognitive or psychiatric symptom before motor symptom onset(28)",
            "aac assessment": "",
            "swallow examination": "",
            "tracheostomy examination": ""
        }
    },
    "assessment plan of care": {
        "contraindications precautions": {
            "cryotherapy contraindications": [],
            "cryotherapy precautions": [],
            "contraindications precautions": [],
            "superficial heat is contraindicated with": [],
            "electrotherapy contraindications precautions include": [],
            "other": [
                "Patients with this diagnosis are at risk for falls; follow facility protocols for fall prevention and post fall-prevention instructions at bedside, if inpatient. Ensure that patient and family/caregivers are aware of the potential for falls and educated about fall-prevention  strategies. Discharge criteria should include independence with fall-prevention strategies",
                "Clinicians should follow the guidelines of their clinic/hospital and what is ordered by the patient\u2019s physician. The summary below is meant to serve as a guide, not to replace orders from a physician or a clinic\u2019s specific protocols(24,25,26,27)",
                "When prescribing exercise, it is important to keep in mind that patients with HD demonstrate a large amount of variability in observed metabolic and physiological responses to exercise and may require altered exercise prescription parameters(18,24)",
                "Check if dysphagia is a problem; note any soft diet, thin liquid restrictions",
                "Caution should be used for restraints in seating and in bed, as restraints can often cause more harm. Clinicians should assess positioning in bed and chair for support and safety",
                "For patients with late-stage  HD who are immobile, clinicians should check frequently for skin breakdown with positioning devices"
            ]
        },
        "diagnosis need for treatment": "Referral to occupational therapy for ADL training and adaptation to maximize independence and for safety and home modifications",
        "rule out": " Rule out Movement disorders caused by infections, medications/drug induced, or metabolic or endocrine dysfunction(1,2,13) Senile chorea(1,13) Essential chorea(1) Parkinson disease(1) Alzheimer disease(1) Creutzfeldt-Jakob  disease(1,2,3,4,5) Frontotemporal lobar degeneration(1,2,3,4,5) Bipolar disorder(1,2,3,4,5) Schizophrenia(1,2,3,4,5) Alcoholism(1,2,3,4,5) Antisocial personality disorder(1,2,3,4,5) Sydenham\u2019s chorea(13) Wilson\u2019s disease(13) Benign hereditary chorea(13) Systemic lupus erythematosus(13) Paraneoplastic conditions (e.g., small-cell  lung cancer, lymphoma)",
        "prognosis": [
            "Disease progresses over the course of 15\u201320  years, resulting in deteriorating function,(11) increasing disability, and death(11,13)",
            "Patients with HD will likely require placement in long-term  care facility as their function deteriorates(1,11)",
            "Common causes of death include infection (such as pneumonia), injuries related to falls, or other complications(1,2,11,13)"
        ],
        "referral to other disciplines": " Referral to other disciplines Physical therapy Speech-language  pathology Respiratory therapy Social work Psychology/psychiatry Nutrition Genetic counseling  Ophthalmology V ocational therapy Support group",
        "other considerations": [
            "Caloric intake is important for persons with HD, as persons with HD have a high energy expenditure due to involuntary movements \u2013Weight loss is a concern",
            "Driving \u2013Even in mild stages, HD can affect driving at many levels due to motor and cognitive deficits, leading to unsafe road performance(19,31) -In a study that compared driving performance of 58 participants with HD (28 with premanifest HD and 30 with manifest HD) and 29 controls, investigators found that individuals with manifest HD demonstrated less vehicle control and slower driving speeds(19) -Psychiatric, postural sway, and neuropsychologicalassessments were performed to evaluate if these measures were a predictor of driving outcomes -Results indicated that measures of postural sway and information processing speed were predictors of driving outcome"
        ],
        "treatment summary": []
    },
    "desired outcomes outcome measures": {
        "desired outcomes and outcome measures ,,,": [
            "Maintaining independent function within limits of disease\u2013FIM, Barthel Index, PPT, UHDRS",
            "Safe participation in daily activities, using adaptive equipment as necessary\u2013BOSH",
            "Decreased risk for falls\u2013Tinetti Gait & Balance Scale, Berg Balance Measure"
        ]
    },
    "maintenance or prevention": [
        "In early-stage  HD, a regular fitness regimen can be useful to maintain physical fitness and prevent depression",
        "In late-stage  HD, prevention of pressure sores and contractures through seating and positioning in wheelchair and bed",
        "As there is no cure for HD, maintaining patient\u2019s quality of life through safety and adaptations to his or her environment is key",
        "Implement fall-prevention  techniques"
    ],
    "patient education": [
        "For information about the disease as well as local support around the world, see the International Huntington Association website at http://huntington-disease.org/  Coding Matrix References are rated using the following codes, listed in order of strength: MPublished meta-analysis SRPublished systematic or integrative literature review RCTPublished research (randomized controlled trial) RPublished research (not randomized controlled trial) CCase histories, case studies GPublished guidelinesRVPublished review of the literature RUPublished research utilization report QIPublished quality improvement report LLegislation PGRPublished government report PFRPublished funded reportPPPolicies, procedures, protocols XPractice exemplars, stories, opinions GIGeneral or background information/texts/reports UUnpublished research, reviews, poster presentations or other such materials CPConference proceedings, abstracts, presentation"
    ],
    "references": [
        {
            "number in article": 1,
            "reference": "Bachoud-L\u00e9vi  A-C, Ferreira J, Massart R, et al. International guidelines for the treatment of Huntington's disease. Front Neurol . 2019;10(710). doi:https://doi.org/10.3389/ fneur.2019.00710. (G)"
        },
        {
            "number in article": 2,
            "reference": "Rosenblatt A. Overview and principles of treatment. In: Lovecky D, Tarapata K, eds. A Physician\u2019s Guide to the Management of Huntington\u2019s Disease . 3rd ed. New York, NY: Huntington\u2019s Disease Society of America; 2011:5-14.  (G)"
        },
        {
            "number in article": 3,
            "reference": "Nance M. Genetic counseling and genetic testing. In: Lovecky D, Tarapata K, eds. A Physician\u2019s Guide to the Management of Huntington\u2019s Disease . 3rd ed. New York, NY: Huntington\u2019s Disease Society of America; 2011:15-26.  (GI)"
        },
        {
            "number in article": 4,
            "reference": "Wheelock V. The motor disorder. In: Lovecky D, Tarapata K, eds. A Physician\u2019s Guide to the Management of Huntington\u2019s Disease . 3rd ed. New York, NY: Huntington\u2019s Disease Society of America; 2011:39-50.  (GI)"
        },
        {
            "number in article": 5,
            "reference": "Rosenblatt A. The psychiatric disorder. In: Lovecky D, Tarapata K, eds. A Physician\u2019s Guide to the Management of Huntington\u2019s Disease . 3rd ed. New York, NY: Huntington\u2019s Disease Society of America; 2011:63-82.  (GI)"
        },
        {
            "number in article": 6,
            "reference": "Paulson HL, Albin RL. Huntington's disease. Lo DC, Hughes RE, eds. Neurobiology of Huntington's Disease: Applications to Drug Discovery . Boca Raton, FL: CRC Press;"
        },
        {
            "number in article": 2011,
            "reference": " (GI)"
        },
        {
            "number in article": 7,
            "reference": "Scahill RI, Zeun P, Osborne-Crowley  K, et al. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS):  A cross-sectional  analysis. Lancet Nerol . 2020;19(6):502-512.  doi:https://doi.org/10.1016/S1474-4422(20)30143-5.  (R)"
        },
        {
            "number in article": 8,
            "reference": "Fritz NE, Busse M, Jones K, Khalil H, Quinn L. A classification system to guide physical therapy management in Huntington Disease: A case series. J Neurol Phys Ther . 2017;41(3):156-163.  doi:https://doi.org/10.1097/NPT.0000000000000188. (C)"
        },
        {
            "number in article": 9,
            "reference": "Maritza R, Tennant A, Fellinghauer C, Stucki G, Prodinger B. The Functional Independence Measure 18-item version can be reported as a unidimensional interval-scaled metric: Iinternal construct validity revisited. J Rehabil Med . 2019;51(3):193-200.  doi:https://doi.org/10.2340/16501977-2525.  (R)"
        },
        {
            "number in article": 10,
            "reference": "Winder JY, Achterberg WP, Gardiner SL, Roos RAC. Longitudinal assessment of the Unified Huntington's Disease Rating Scale (UHDRS) and UHDRS\u2013For  Advanced Patients (UHDRS-FAP)  in patients with late stage Huntington's disease. Eur J Neurol . 2019;26(5):780-785.  doi:https://doi.org/10.1111/ene.13889. (R)"
        },
        {
            "number in article": 11,
            "reference": "Nance M. Management of late stage Huntington\u2019s disease. In: Lovecky D, Tarapata K, eds. A Physician\u2019s Guide to the Management of Huntington\u2019s Diseas . 3rd ed. New York, NY: Huntington\u2019s Disease Society of America; 2011:99-114.  (GI)"
        },
        {
            "number in article": 12,
            "reference": "Cook C, Page K, Wagstaff A, Simpson SA, Rae D. Development of guidelines for occupational therapy in Huntington\u2019s disease. Neurodegenerative Dis Manage . 2012;2(1):79-87.  (SR)"
        },
        {
            "number in article": 13,
            "reference": "Jolly A, Kass JS, Jamal F. Huntington's disease. Ferri FF, ed. Ferri's clinical advisor: 5 books in 1 . Philadelphia, PA: Elsevier; 2021. (GI)"
        },
        {
            "number in article": 14,
            "reference": "Rawlins MD, Wexler NS, Wexler AR, et al. The prevalence of Huntington's disease. Neuroepidemiology . 2016;46(2):144-153.  doi:https://doi.org/10.1159/000443738. (SR)"
        },
        {
            "number in article": 15,
            "reference": "Yohrling G, Raimundo K, Crowell V, Lovecky D, Vetter L, Seeberger L. Prevalence of Huntington\u2019s disease in the US (954). Neurology . 2020;94(15 Supplement):954. (GI)"
        },
        {
            "number in article": 16,
            "reference": "Stout JC, Queller S, Baker KN, et al. A cognitive assessment battery for clinical trials in Huntington\u2019s disease 1,2,3. Mov Disord . 2014;29(10):1281-1288.  doi:10.1002/ mds.25964. (R)"
        },
        {
            "number in article": 17,
            "reference": "Paulsen JS, Long JD. Onset of Huntington\u2019s disease: Can it be purely cognitive? Mov Disord . 2014;29(11):1342-1350.  doi:10.1002/mds.25997. (R)"
        },
        {
            "number in article": 18,
            "reference": "Dawes H, Collett J, Debono K, et al. Exercise testing and training in people with Huntington\u2019s disease. Clin Rehabil . 2015;29(2):196-206.  doi:10.1177/0269215514540921. (RCT)"
        },
        {
            "number in article": 19,
            "reference": "Jacobs M, Hart EP, Mejia Miranda Y, Groeneveld GJ, van Gerven JMA, Roos RAC. Predictors of simulated driving performance in Huntington\u2019s disease. Parkinsonism Relat Disord. 2019;60:64-69.  doi:https://doi.org/10.1016/j.parkreldis.2018.10.002. (R)"
        },
        {
            "number in article": 20,
            "reference": "Rothing M, Malterud K, Frich JC. Caregiver roles in families affected by Huntington\u2019s disease: A qualitative interview study. Scand J Caring Sci . 2014;28(4):700-705. doi:10.1111/scs.12098. (R)"
        },
        {
            "number in article": 21,
            "reference": "Kavanaugh M. Children and adolescents providing care to a parent with Huntington\u2019s disease: Disease symptoms, caregiving tasks and young carer well-being.  Child Youth Care Forum . 2014;43(6):675-690.  doi:10.1007/s10566-014-9258-x.  (R)"
        },
        {
            "number in article": 22,
            "reference": "Lazar AS, Panin F, et al. Sleep deficits but no metabolic deficits in premanifest Huntington\u2019s disease. Ann Neurol . 2015;78(4):630-648.  doi:10.1002/ana.24495. (R)"
        },
        {
            "number in article": 23,
            "reference": "Frank S, Testa CM, Stamler D, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316(1):40-50. doi:10.1001/jama.2016.8655. (RCT)"
        },
        {
            "number in article": 24,
            "reference": "Fritz NE, Rao AK, Kegelmeyer D, et al. Physical therapy and exercise interventions in Huntington\u2019s disease: A mixed methods systematic review. J Huntingtons Dis . 2017;6(3):217-235.  doi:https://doi.org/10.11124/JBISRIR-2016-003274.  (SR)"
        },
        {
            "number in article": 25,
            "reference": "van Walsem MR, Piira A, Mikalsen G, et al. Cognitive performance after a one-year multidisciplinary intensive rehabilitation program for Huntington\u2019s disease: An observational study. J Huntingtons Dis . 2018;7(4):379-389.  doi:https://doi.org/10.3233/JHD-180294.  (R)"
        },
        {
            "number in article": 26,
            "reference": "Bartlett DM, Govus A, Rankin T, et al. The effects of multidisciplinary rehabilitation on neuroimaging, biological, cognitive and motor outcomes in individuals with premanifest Huntington's disease. J Neurol Sci . 2020;416:117022. doi:https://doi.org/10.1016/j.jns.2020.117022. (R)"
        },
        {
            "number in article": 27,
            "reference": "Prodinger B, O'Connor RJ, Stucki G, Tennant A. Establishing score equivalence of the Functional Independence Measure motor scale and the Barthel Index, utilizing the International Classification of Functioning, Disability and Health and Rasch measurement theory. J Rehabil Med . 2017;49(5):416-422. doi:https://doi.org/10.2340/16501977-2225.  (R)"
        },
        {
            "number in article": 28,
            "reference": "McAllister B, Gusella JF, Landwehrmeyer GB, et al. The timing and impact of psychiatric, cognitive and motor manifestations of Huntington\u2019s disease. bioRxiv. 2020. doi:https:// doi.org/10.1101/2020.05.26.116798. (U)"
        },
        {
            "number in article": 29,
            "reference": "Quinn L, Kegelmeyer D, Kloos A, Rao AK, Busse M, Fritz NE. Clinical recommendations to guide physical therapy practice for Huntington disease. Neurology . 2020;94(5):217-228.  doi:https://doi.org/10.1212/WNL.0000000000008887. (SR)"
        },
        {
            "number in article": 30,
            "reference": "Paulsen JS. The cognitive disorder. In: Lovecky D, Tarapata K, eds. A Physician\u2019s Guide to the Management of Huntington\u2019s Disease . 3rd ed. New York, NY: Huntington\u2019s Disease Society of America; 2011:51-62.  (GI)"
        },
        {
            "number in article": 31,
            "reference": "Nance M, Rosenblatt A. Team care for Huntington\u2019s disease & driving cessation in Huntington\u2019s disease. In: Lovecky D, Tarapata K, eds. A Physician\u2019s Guide to the Management of Huntington\u2019s Disease . 3rd ed. New York, NY: Huntington\u2019s Disease Society of America; 2011:27-38.  (G)"
        },
        {
            "number in article": 32,
            "reference": "Jones J, Thompson M. Implications of Huntington\u2019s Disease on Daily Living: An Educational Tool and Guide for Occupational Therapists Treating Individuals with Huntington\u2019s Disease. 2015; [master\u2019s thesis]. (U)"
        }
    ]
}